Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5021 - Soft tissue sarcomas express a distinct mRNA immune profile

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Soft Tissue Sarcomas

Presenters

Viktor Grünwald

Citation

Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283

Authors

V. Grünwald1, F. Laenger2, A. Kunitz3, M. Schuler4, P. Schoeffski5, H. Kopp6, S. Bauer7, B. Kasper8, L. Lindner9, J.M. Chemnitz10, M. Crysandt11, A. Stein12, B. Steffen13, M. Kneba14, G. Egerer15, S. Zimmermann16, P. Ivanyi17, A. Karch18

Author affiliations

  • 1 Clinic For Cancer Research And Clinic For Urology, University Hospital Essen Westdeutsches Tumorzentrum, 45122 - Essen/DE
  • 2 Pathology, Medical School Hannover, 30625 - Hannover/DE
  • 3 Hematology & Oncology, Vivantes Klinikum Spandau, 13585 - Berlin/DE
  • 4 Hematology & Oncology, Helios Klinikum Emil von Behring, 14165 - Berlin/DE
  • 5 Medical Oncology, University Hospitals Leuven, 3000 - Leuven/BE
  • 6 Oncology/hematology, Robert-Bosch-Krankenhaus, 70376 - Stuttgart/DE
  • 7 Medical Oncology Department, University Hospital Essen Westdeutsches Tumorzentrum, 45147 - Essen/DE
  • 8 Interdisciplinary Cancer Center, University Hospital Mannheim, 68167 - Mannheim/DE
  • 9 Medical Oncology, University Hospital Munich, 81377 - Munich/DE
  • 10 Medical Oncology, Gemeinschaftsklinikum Mittlerhein, 56073 - Koblenz/DE
  • 11 Hematology & Oncology, University Hospital Aachen, 52047 - Aachen/DE
  • 12 Private Practice, Hematological and oncological practice Eppendorf, 20246 - Hamburg/DE
  • 13 Hematology & Oncology, University Hospital Frankfurt, 60590 - Frankfurt/DE
  • 14 Hematology & Oncology, UK-SH, Campus Kiel, 24105 - Kiel/DE
  • 15 Hematology & Oncology, University Hospital Heidelberg, 69115 - Heidelberg/DE
  • 16 Hannover Clinical Trial Center, Medical School Hannover, 30625 - Hannover/DE
  • 17 Hematology & Oncology, Hannover Medical School, 30625 - Hannover/DE
  • 18 Biostatistics, Medical School Hannover, 30625 - Hannover/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5021

Background

There is a need for novel therapies in metastatic STS, rendering checkpoint inhibitors (CPI) of interest in STS. Immune cell infiltrates are thought as a prerequisite for CPI efficacy and its role remains vague in STS. We analyzed whether the immune profile differed for STS treated within the phase II EPAZ study (NCT01861951).

Methods

RNA samples were measured using the PanCancer Immune Profiling Panel from the nCounter® Analysis System. FCF1, HDAC3, ZKSCAN5, MRPS5 and EIF2B4 were used as housekeeping genes. Samples were categorized in three groups based on their overall mRNA expression via unsupervised random forest analysis. Differences in gene expression were tested by T-tests or ANOVA, with correction for multiple testing. Ingenuity Pathway Analysis (IPA) were performed for activity prediction. K-M plots were used for survival estimates and log-rank analyses for comparisons.

Results

Specimens were available in 70/120 patients and 31 were assessable by immune profiling. 12 pts. received doxorubicin (DOX) and 18 pazopanib (PAZ). Median progression free survival (PFS) and median overall survival (OS) for the total cohort were 2.6 mo. and 11.6 mo., respectively. Patients were clustered in high (n = 4)/mixed (n = 20)/low (n = 7) mRNA profile expressions. While OS varied numerically between clusters (11.1/9.0/28.9 mo.), values were not significant (P = 0.5573). A similar pattern was detected for PFS (4.2/1.5/8.9 mo.; P = 0.4127).

Conclusions

Our study indicates that STS express a differential mRNA immune profile. However, clusters were not associated with outcome measures. A major limitation is the small sample size.

Clinical trial identification

NCT01861951.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

V. Grünwald: Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self): PharmaMar. M. Schuler: Research grant / Funding (institution): Novartis. P. Schoeffski: Honoraria (institution), Advisory / Consultancy: Daiichi; Honoraria (institution), Advisory / Consultancy: Eisai; Honoraria (institution), Advisory / Consultancy: Lilly; Honoraria (institution), Advisory / Consultancy: Medpace; Honoraria (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (institution): Biovitrium; Honoraria (institution): 6th element capital; Advisory / Consultancy, Travel / Accommodation / Expenses: Adaptimmune; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Blueprint; Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: BoBoehringer Ingelheim; Advisory / Consultancy, Travel / Accommodation / Expenses: Cristal Therapeutics; Advisory / Consultancy, Travel / Accommodation / Expenses: Epizyme; Advisory / Consultancy, Travel / Accommodation / Expenses: Genzyme; Advisory / Consultancy, Travel / Accommodation / Expenses: Ipsen; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Loxo Oncology; Advisory / Consultancy, Travel / Accommodation / Expenses: Nektar; Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis. H. Kopp: Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Speaker Bureau / Expert testimony: LeoPharma; Speaker Bureau / Expert testimony: Pfizer; Travel / Accommodation / Expenses: Lilly; Travel / Accommodation / Expenses: Amgen. B. Kasper: Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Novartis; Advisory / Consultancy: Eisai ; Honoraria (self), Research grant / Funding (institution): PharmaMar. L. Lindner: Advisory / Consultancy: Novartis; Honoraria (self): Lilly; Honoraria (self): Eisai; Honoraria (self): EZ Medconsultant; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: PharmaMar; Research grant / Funding (institution): Sennewald. J.M. Chemnitz: Honoraria (self): Ablynx; Advisory / Consultancy: Amgen; Advisory / Consultancy: Ablynx; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: PharmaMar. G. Egerer: Honoraria (self): MSD; Advisory / Consultancy: MSD; Honoraria (self): PharmaMar; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Astellas. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.